Pharma Key Molecule Check - Traction In Key Dr. Reddy's, Lupin, Ajanta Pharma Products: Yes Securities
Ajanta Pharma has seen market share gains across top products which should aid base business.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Yes Securities Report
In this report, we take a look at the key molecules for generic pharma companies and assess market share swings which can have a bearing on Q2 U.S. performance.
While price erosion trend remains potentially stable QoQ thereby easing pressure on base business, reckon examining important molecules can offer additional qualitative indication of strength in U.S. business.
We looked at several molecules like Brinzolamide/Combigan, Revlimid, key Lupin Ltd. products and top molecules of Ajanta Pharma Ltd., Alembic Pharmaceuticals Ltd. and Torrent Pharmaceuticals Ltd. Takeaways include-
Indoco Remedies Ltd. could struggle due to flat Brinzo market share,
Dr Reddy's Laboratories Ltd.'s gaining traction in Revlimid QoQ,
Lupin is off to a good start in Spiriva while other notable launches like Darunavir, Lisinopril are doing well – points to a healthy U.S. performance QoQ,
Ajanta Pharma has seen market share gains across top products which should aid base business while Alembic Pharma and Torrent Pharma not seeing much market share swings in key respective products.
Notwithstanding U.S. performance in Q2, we stick to our preferred names like Ajanta Pharma and Indoco Remedies while retain Vijaya Diagnostic Centre Ltd. over Dr Lal PathLabs Ltd. and Metropolis Healthcare Ltd. in diagnostics.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.